QURE AI BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Qure.ai's BCG Matrix snapshot highlights where its AI-driven diagnostic tools likely sit across growth and market-share dynamics-identifying potential Stars in advanced imaging, Question Marks among emerging modalities, and Cash Cows in established workflow products. This concise view frames strategic trade-offs between scaling R&D and harvesting mature offerings. Purchase the full BCG Matrix to unlock quadrant-by-quadrant placement, data-backed recommendations, and ready-to-use Word and Excel deliverables that translate analysis into actionable investment and product decisions.
Stars
qXR Chest X-ray AI with 1.5 Million Monthly Scans
qXR Chest X-ray AI handles 1.5 million scans monthly, dominating high-volume radiography with >95% sensitivity for key findings and sub-1% false positives in peer studies.
By late 2025, Qure AI integrated qXR into workflows at hospitals across 90+ countries, driving an estimated 28% global market share in automated chest x‑ray solutions.
Growth ties to public health drives: Qure AI is primary partner on TB and early lung cancer screening programs, contributing to ~40% of screened populations in partnered initiatives and adding $45M ARR in 2025.
qER Head CT for Emergency Care with 3 Minute Turnaround
qER Head CT for Emergency Care delivers a 3-minute turnaround and is FDA-cleared to prioritize critical stroke and trauma cases; by FY2025 it's deployed in over 420 U.S. hospitals, driving a 28% reduction in door-to-treatment time in published clinical audits.
qLung Nodule Management with 40 Percent Annual Growth
qLung Nodule Management shows ~40% annual revenue growth, reaching an estimated $58M ARR in FY2025 after rapid adoption following US and EU lung cancer screening mandates.
Qure AI captures ~35% market share in automated nodule detection, integrating into oncology PACS and EMR workflows across 420 hospitals by March 2026.
The product burns roughly $14M in annual R&D (FY2025) to sustain algorithm updates and regulatory upkeep, supporting a 60% gross margin and strong retention.
High growth, leading share, and heavy R&D make qLung a BCG Matrix Star-scaling revenue while requiring continued investment to keep dominance.
Pharma Partnership Revenue Exceeding 35 Million Dollars
Pharma partnership revenue exceeded $35 million in FY2025, driven by deals with AstraZeneca and others that use Qure AI's datasets to flag therapy-ready patients; this segment grew ~45% YoY versus 12% hospital-sales growth.
These collaborations shorten trial enrollment, boost drug-market access, and made life-sciences revenue 28% of total FY2025 sales, marking a strategic shift from hospital-focused sales.
- FY2025 pharma revenue: $35M+
- Segment YoY growth: ~45%
- Hospital-sales growth: ~12% YoY
- Life-sciences share: 28% of FY2025 sales
US Market Revenue Increase of 50 Percent in 2025
Qure AI's US-focused pivot drove a 50% revenue rise in 2025 to $45.0M, capturing ~12% of the US AI-radiology market by outperforming incumbents on AUC and throughput.
Targeting high-reimbursement sites lifted gross margin to ~65% despite $9.2M in US sales and regulatory spend; CAC fell 18% as adoption accelerated.
- 2025 revenue: $45.0M
- US market share: ~12%
- Gross margin: ~65%
- US ops spend: $9.2M
- CAC reduction: 18%
qLung FY25: $58M ARR, 40% YoY, 35% nodule share; qXR 1.5M/mo, 60-65% gross
qLung (Star): FY2025 ARR $58M, ~40% YoY growth, 35% market share in nodule detection; qXR handles 1.5M scans/month, 28% global share; qER in 420+ U.S. hospitals; FY2025 R&D $14M, gross margin ~60-65%; pharma revenue $35M (28% sales).
| Metric | FY2025 |
|---|---|
| qLung ARR | $58M |
| qXR scans/month | 1.5M |
| Market share (nodule) | 35% |
| qER US hospitals | 420+ |
| R&D | $14M |
| Gross margin | 60-65% |
| Pharma revenue | $35M |
What is included in the product
Detailed Word Document
Concise BCG Matrix for Qure.ai: identifies Stars, Cash Cows, Question Marks, and Dogs with buy/hold/sell guidance and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Qure AI BCG Matrix placing each product in a quadrant for quick strategic clarity.
Cash Cows
Global Health TB Screening Programs in 50 Plus Countries
Qure AI's Global Health TB screening in 50+ countries is a cash cow: as market leader-partnering with WHO and NGOs-it delivered roughly $18-22M revenue in FY2025 with ~65% gross margins, thanks to low churn and limited local competition.
Core SaaS Subscription Renewals at 95 Percent Rate
The core SaaS subscription renewals at a 95 percent rate generate predictable revenue-Qure AI reported recurring SaaS revenue of $42.6 million in FY2025, with long-term hospital contracts forming the base layer that funds operations.
Clients have integrated Qure AI into their PACS (picture archiving and communication systems), creating high switching costs and low maintenance expense; estimated customer lifetime value rises to $1.2 million for enterprise hospitals.
This stable cash flow preserves liquidity-Qure AI held $28.4 million in cash and equivalents at FY2025 year-end-letting management fund experimental AI feature bets without threatening solvency.
Legacy PACS Integration Middleware and Licenses
Legacy PACS integration middleware and license sales at Qure AI generate steady revenue, comprising an estimated $18.5M in 2025 recurring revenues and ~62% gross margin, reflecting high hospital market share and low churn.
The software needs minimal marketing spend-OPEX down 8% YoY-and contributes stable cash flow that funds R&D for newer AI imaging products.
We classify it as a cash cow: mature, high-share, low-growth but crucial for infrastructure and cross-sell, supporting 2025 capex of $3.2M for platform upkeep.
Automated Radiology Reporting for Standardized Exams
Automated Radiology Reporting for Standardized Exams is a cash cow for Qure AI: growth in core accuracy has plateaued, but volume is huge-handling ~25 million routine reads annually across partners (2025), netting ~45-55% gross margins and contributing roughly $40M revenue in FY2025.
It converts past R&D into steady profits, processing low-complexity cases with minimal incremental cost and freeing resources for advanced product bets.
- Plateaued tech, stable demand
- ~25M exams/year (2025)
- $40M revenue, 45-55% gross margin (FY2025)
- High volume, low incremental cost
Professional Services and Clinical Validation Consulting
Qure AI's Professional Services and Clinical Validation Consulting turns decade-long expertise into high-margin services for smaller hospitals and research centers, generating predictable revenue without new R&D spend; in FY2025 these services contributed roughly $4.2M in revenue and ~65% gross margin, per company disclosures.
As a cash cow, this offering converts Qure AI's brand authority into immediate, low-overhead liquidity, supporting cash flow and funding product innovation while maintaining ~12% YoY revenue stability in 2025.
- FY2025 revenue: $4.2M
- Gross margin: ~65%
- YoY stability: ~12%
- Low incremental cost; leverages existing expertise
Qure AI FY25: $125M+ revenue mix - Core SaaS & Auto‑Reporting drive high-margin cash flow
Qure AI cash cows (FY2025): Global TB screening $20M rev, 65% GM; Core SaaS $42.6M rev, 95% renewal; PACS middleware $18.5M rev, 62% GM; Automated reporting $40M rev, 50% GM; Professional services $4.2M rev, 65% GM; cash $28.4M; capex $3.2M.
| Product | FY2025 Rev | Gross Margin |
|---|---|---|
| Global TB | $20M | 65% |
| Core SaaS | $42.6M | - |
| PACS middleware | $18.5M | 62% |
| Auto Reporting | $40M | 50% |
| Services | $4.2M | 65% |
What You See Is What You Get
Qure AI BCG Matrix
The preview you see is the exact Qure AI BCG Matrix file you'll receive after purchase-no watermarks, no demo placeholders-just a fully formatted, analysis-ready report built for immediate use in presentations or strategic plans.
QURE AI BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Qure.ai's BCG Matrix snapshot highlights where its AI-driven diagnostic tools likely sit across growth and market-share dynamics-identifying potential Stars in advanced imaging, Question Marks among emerging modalities, and Cash Cows in established workflow products. This concise view frames strategic trade-offs between scaling R&D and harvesting mature offerings. Purchase the full BCG Matrix to unlock quadrant-by-quadrant placement, data-backed recommendations, and ready-to-use Word and Excel deliverables that translate analysis into actionable investment and product decisions.
Stars
qXR Chest X-ray AI with 1.5 Million Monthly Scans
qXR Chest X-ray AI handles 1.5 million scans monthly, dominating high-volume radiography with >95% sensitivity for key findings and sub-1% false positives in peer studies.
By late 2025, Qure AI integrated qXR into workflows at hospitals across 90+ countries, driving an estimated 28% global market share in automated chest x‑ray solutions.
Growth ties to public health drives: Qure AI is primary partner on TB and early lung cancer screening programs, contributing to ~40% of screened populations in partnered initiatives and adding $45M ARR in 2025.
qER Head CT for Emergency Care with 3 Minute Turnaround
qER Head CT for Emergency Care delivers a 3-minute turnaround and is FDA-cleared to prioritize critical stroke and trauma cases; by FY2025 it's deployed in over 420 U.S. hospitals, driving a 28% reduction in door-to-treatment time in published clinical audits.
qLung Nodule Management with 40 Percent Annual Growth
qLung Nodule Management shows ~40% annual revenue growth, reaching an estimated $58M ARR in FY2025 after rapid adoption following US and EU lung cancer screening mandates.
Qure AI captures ~35% market share in automated nodule detection, integrating into oncology PACS and EMR workflows across 420 hospitals by March 2026.
The product burns roughly $14M in annual R&D (FY2025) to sustain algorithm updates and regulatory upkeep, supporting a 60% gross margin and strong retention.
High growth, leading share, and heavy R&D make qLung a BCG Matrix Star-scaling revenue while requiring continued investment to keep dominance.
Pharma Partnership Revenue Exceeding 35 Million Dollars
Pharma partnership revenue exceeded $35 million in FY2025, driven by deals with AstraZeneca and others that use Qure AI's datasets to flag therapy-ready patients; this segment grew ~45% YoY versus 12% hospital-sales growth.
These collaborations shorten trial enrollment, boost drug-market access, and made life-sciences revenue 28% of total FY2025 sales, marking a strategic shift from hospital-focused sales.
- FY2025 pharma revenue: $35M+
- Segment YoY growth: ~45%
- Hospital-sales growth: ~12% YoY
- Life-sciences share: 28% of FY2025 sales
US Market Revenue Increase of 50 Percent in 2025
Qure AI's US-focused pivot drove a 50% revenue rise in 2025 to $45.0M, capturing ~12% of the US AI-radiology market by outperforming incumbents on AUC and throughput.
Targeting high-reimbursement sites lifted gross margin to ~65% despite $9.2M in US sales and regulatory spend; CAC fell 18% as adoption accelerated.
- 2025 revenue: $45.0M
- US market share: ~12%
- Gross margin: ~65%
- US ops spend: $9.2M
- CAC reduction: 18%
qLung FY25: $58M ARR, 40% YoY, 35% nodule share; qXR 1.5M/mo, 60-65% gross
qLung (Star): FY2025 ARR $58M, ~40% YoY growth, 35% market share in nodule detection; qXR handles 1.5M scans/month, 28% global share; qER in 420+ U.S. hospitals; FY2025 R&D $14M, gross margin ~60-65%; pharma revenue $35M (28% sales).
| Metric | FY2025 |
|---|---|
| qLung ARR | $58M |
| qXR scans/month | 1.5M |
| Market share (nodule) | 35% |
| qER US hospitals | 420+ |
| R&D | $14M |
| Gross margin | 60-65% |
| Pharma revenue | $35M |
What is included in the product
Detailed Word Document
Concise BCG Matrix for Qure.ai: identifies Stars, Cash Cows, Question Marks, and Dogs with buy/hold/sell guidance and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Qure AI BCG Matrix placing each product in a quadrant for quick strategic clarity.
Cash Cows
Global Health TB Screening Programs in 50 Plus Countries
Qure AI's Global Health TB screening in 50+ countries is a cash cow: as market leader-partnering with WHO and NGOs-it delivered roughly $18-22M revenue in FY2025 with ~65% gross margins, thanks to low churn and limited local competition.
Core SaaS Subscription Renewals at 95 Percent Rate
The core SaaS subscription renewals at a 95 percent rate generate predictable revenue-Qure AI reported recurring SaaS revenue of $42.6 million in FY2025, with long-term hospital contracts forming the base layer that funds operations.
Clients have integrated Qure AI into their PACS (picture archiving and communication systems), creating high switching costs and low maintenance expense; estimated customer lifetime value rises to $1.2 million for enterprise hospitals.
This stable cash flow preserves liquidity-Qure AI held $28.4 million in cash and equivalents at FY2025 year-end-letting management fund experimental AI feature bets without threatening solvency.
Legacy PACS Integration Middleware and Licenses
Legacy PACS integration middleware and license sales at Qure AI generate steady revenue, comprising an estimated $18.5M in 2025 recurring revenues and ~62% gross margin, reflecting high hospital market share and low churn.
The software needs minimal marketing spend-OPEX down 8% YoY-and contributes stable cash flow that funds R&D for newer AI imaging products.
We classify it as a cash cow: mature, high-share, low-growth but crucial for infrastructure and cross-sell, supporting 2025 capex of $3.2M for platform upkeep.
Automated Radiology Reporting for Standardized Exams
Automated Radiology Reporting for Standardized Exams is a cash cow for Qure AI: growth in core accuracy has plateaued, but volume is huge-handling ~25 million routine reads annually across partners (2025), netting ~45-55% gross margins and contributing roughly $40M revenue in FY2025.
It converts past R&D into steady profits, processing low-complexity cases with minimal incremental cost and freeing resources for advanced product bets.
- Plateaued tech, stable demand
- ~25M exams/year (2025)
- $40M revenue, 45-55% gross margin (FY2025)
- High volume, low incremental cost
Professional Services and Clinical Validation Consulting
Qure AI's Professional Services and Clinical Validation Consulting turns decade-long expertise into high-margin services for smaller hospitals and research centers, generating predictable revenue without new R&D spend; in FY2025 these services contributed roughly $4.2M in revenue and ~65% gross margin, per company disclosures.
As a cash cow, this offering converts Qure AI's brand authority into immediate, low-overhead liquidity, supporting cash flow and funding product innovation while maintaining ~12% YoY revenue stability in 2025.
- FY2025 revenue: $4.2M
- Gross margin: ~65%
- YoY stability: ~12%
- Low incremental cost; leverages existing expertise
Qure AI FY25: $125M+ revenue mix - Core SaaS & Auto‑Reporting drive high-margin cash flow
Qure AI cash cows (FY2025): Global TB screening $20M rev, 65% GM; Core SaaS $42.6M rev, 95% renewal; PACS middleware $18.5M rev, 62% GM; Automated reporting $40M rev, 50% GM; Professional services $4.2M rev, 65% GM; cash $28.4M; capex $3.2M.
| Product | FY2025 Rev | Gross Margin |
|---|---|---|
| Global TB | $20M | 65% |
| Core SaaS | $42.6M | - |
| PACS middleware | $18.5M | 62% |
| Auto Reporting | $40M | 50% |
| Services | $4.2M | 65% |
What You See Is What You Get
Qure AI BCG Matrix
The preview you see is the exact Qure AI BCG Matrix file you'll receive after purchase-no watermarks, no demo placeholders-just a fully formatted, analysis-ready report built for immediate use in presentations or strategic plans.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Qure.ai's BCG Matrix snapshot highlights where its AI-driven diagnostic tools likely sit across growth and market-share dynamics-identifying potential Stars in advanced imaging, Question Marks among emerging modalities, and Cash Cows in established workflow products. This concise view frames strategic trade-offs between scaling R&D and harvesting mature offerings. Purchase the full BCG Matrix to unlock quadrant-by-quadrant placement, data-backed recommendations, and ready-to-use Word and Excel deliverables that translate analysis into actionable investment and product decisions.
Stars
qXR Chest X-ray AI with 1.5 Million Monthly Scans
qXR Chest X-ray AI handles 1.5 million scans monthly, dominating high-volume radiography with >95% sensitivity for key findings and sub-1% false positives in peer studies.
By late 2025, Qure AI integrated qXR into workflows at hospitals across 90+ countries, driving an estimated 28% global market share in automated chest x‑ray solutions.
Growth ties to public health drives: Qure AI is primary partner on TB and early lung cancer screening programs, contributing to ~40% of screened populations in partnered initiatives and adding $45M ARR in 2025.
qER Head CT for Emergency Care with 3 Minute Turnaround
qER Head CT for Emergency Care delivers a 3-minute turnaround and is FDA-cleared to prioritize critical stroke and trauma cases; by FY2025 it's deployed in over 420 U.S. hospitals, driving a 28% reduction in door-to-treatment time in published clinical audits.
qLung Nodule Management with 40 Percent Annual Growth
qLung Nodule Management shows ~40% annual revenue growth, reaching an estimated $58M ARR in FY2025 after rapid adoption following US and EU lung cancer screening mandates.
Qure AI captures ~35% market share in automated nodule detection, integrating into oncology PACS and EMR workflows across 420 hospitals by March 2026.
The product burns roughly $14M in annual R&D (FY2025) to sustain algorithm updates and regulatory upkeep, supporting a 60% gross margin and strong retention.
High growth, leading share, and heavy R&D make qLung a BCG Matrix Star-scaling revenue while requiring continued investment to keep dominance.
Pharma Partnership Revenue Exceeding 35 Million Dollars
Pharma partnership revenue exceeded $35 million in FY2025, driven by deals with AstraZeneca and others that use Qure AI's datasets to flag therapy-ready patients; this segment grew ~45% YoY versus 12% hospital-sales growth.
These collaborations shorten trial enrollment, boost drug-market access, and made life-sciences revenue 28% of total FY2025 sales, marking a strategic shift from hospital-focused sales.
- FY2025 pharma revenue: $35M+
- Segment YoY growth: ~45%
- Hospital-sales growth: ~12% YoY
- Life-sciences share: 28% of FY2025 sales
US Market Revenue Increase of 50 Percent in 2025
Qure AI's US-focused pivot drove a 50% revenue rise in 2025 to $45.0M, capturing ~12% of the US AI-radiology market by outperforming incumbents on AUC and throughput.
Targeting high-reimbursement sites lifted gross margin to ~65% despite $9.2M in US sales and regulatory spend; CAC fell 18% as adoption accelerated.
- 2025 revenue: $45.0M
- US market share: ~12%
- Gross margin: ~65%
- US ops spend: $9.2M
- CAC reduction: 18%
qLung FY25: $58M ARR, 40% YoY, 35% nodule share; qXR 1.5M/mo, 60-65% gross
qLung (Star): FY2025 ARR $58M, ~40% YoY growth, 35% market share in nodule detection; qXR handles 1.5M scans/month, 28% global share; qER in 420+ U.S. hospitals; FY2025 R&D $14M, gross margin ~60-65%; pharma revenue $35M (28% sales).
| Metric | FY2025 |
|---|---|
| qLung ARR | $58M |
| qXR scans/month | 1.5M |
| Market share (nodule) | 35% |
| qER US hospitals | 420+ |
| R&D | $14M |
| Gross margin | 60-65% |
| Pharma revenue | $35M |
What is included in the product
Detailed Word Document
Concise BCG Matrix for Qure.ai: identifies Stars, Cash Cows, Question Marks, and Dogs with buy/hold/sell guidance and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Qure AI BCG Matrix placing each product in a quadrant for quick strategic clarity.
Cash Cows
Global Health TB Screening Programs in 50 Plus Countries
Qure AI's Global Health TB screening in 50+ countries is a cash cow: as market leader-partnering with WHO and NGOs-it delivered roughly $18-22M revenue in FY2025 with ~65% gross margins, thanks to low churn and limited local competition.
Core SaaS Subscription Renewals at 95 Percent Rate
The core SaaS subscription renewals at a 95 percent rate generate predictable revenue-Qure AI reported recurring SaaS revenue of $42.6 million in FY2025, with long-term hospital contracts forming the base layer that funds operations.
Clients have integrated Qure AI into their PACS (picture archiving and communication systems), creating high switching costs and low maintenance expense; estimated customer lifetime value rises to $1.2 million for enterprise hospitals.
This stable cash flow preserves liquidity-Qure AI held $28.4 million in cash and equivalents at FY2025 year-end-letting management fund experimental AI feature bets without threatening solvency.
Legacy PACS Integration Middleware and Licenses
Legacy PACS integration middleware and license sales at Qure AI generate steady revenue, comprising an estimated $18.5M in 2025 recurring revenues and ~62% gross margin, reflecting high hospital market share and low churn.
The software needs minimal marketing spend-OPEX down 8% YoY-and contributes stable cash flow that funds R&D for newer AI imaging products.
We classify it as a cash cow: mature, high-share, low-growth but crucial for infrastructure and cross-sell, supporting 2025 capex of $3.2M for platform upkeep.
Automated Radiology Reporting for Standardized Exams
Automated Radiology Reporting for Standardized Exams is a cash cow for Qure AI: growth in core accuracy has plateaued, but volume is huge-handling ~25 million routine reads annually across partners (2025), netting ~45-55% gross margins and contributing roughly $40M revenue in FY2025.
It converts past R&D into steady profits, processing low-complexity cases with minimal incremental cost and freeing resources for advanced product bets.
- Plateaued tech, stable demand
- ~25M exams/year (2025)
- $40M revenue, 45-55% gross margin (FY2025)
- High volume, low incremental cost
Professional Services and Clinical Validation Consulting
Qure AI's Professional Services and Clinical Validation Consulting turns decade-long expertise into high-margin services for smaller hospitals and research centers, generating predictable revenue without new R&D spend; in FY2025 these services contributed roughly $4.2M in revenue and ~65% gross margin, per company disclosures.
As a cash cow, this offering converts Qure AI's brand authority into immediate, low-overhead liquidity, supporting cash flow and funding product innovation while maintaining ~12% YoY revenue stability in 2025.
- FY2025 revenue: $4.2M
- Gross margin: ~65%
- YoY stability: ~12%
- Low incremental cost; leverages existing expertise
Qure AI FY25: $125M+ revenue mix - Core SaaS & Auto‑Reporting drive high-margin cash flow
Qure AI cash cows (FY2025): Global TB screening $20M rev, 65% GM; Core SaaS $42.6M rev, 95% renewal; PACS middleware $18.5M rev, 62% GM; Automated reporting $40M rev, 50% GM; Professional services $4.2M rev, 65% GM; cash $28.4M; capex $3.2M.
| Product | FY2025 Rev | Gross Margin |
|---|---|---|
| Global TB | $20M | 65% |
| Core SaaS | $42.6M | - |
| PACS middleware | $18.5M | 62% |
| Auto Reporting | $40M | 50% |
| Services | $4.2M | 65% |
What You See Is What You Get
Qure AI BCG Matrix
The preview you see is the exact Qure AI BCG Matrix file you'll receive after purchase-no watermarks, no demo placeholders-just a fully formatted, analysis-ready report built for immediate use in presentations or strategic plans.
